Lifeward Outlines Growth Strategy with Focus on Rehabilitation and Biomedical Expansion
Event summary
- Lifeward published an updated investor presentation on September 8, 2026, detailing its commercial growth strategy.
- The strategy focuses on scaling its neurorehabilitation platform, leveraging reimbursement infrastructure, and expanding its distribution network.
- The presentation highlights recent commercial performance, product development pipeline, and partnership with Oramed Pharmaceuticals.
- Lifeward's portfolio includes ReWalk Exoskeleton, AlterG Anti-Gravity system, MyoCycle FES System, and ReStore Exo-Suit.
- The company is diversifying into high-value therapeutic platforms, including its Protein Oral Delivery (POD™) platform for oral biologic drugs.
The big picture
Lifeward is positioning itself as a diversified biomedical innovator, expanding beyond neurorehabilitation into high-value therapeutic platforms. The company's strategy aligns with broader industry trends toward capital-efficient growth and strategic partnerships. Success will depend on its ability to integrate new technologies while maintaining leadership in its core markets.
What we're watching
- Commercial Execution
- How Lifeward will scale its established rehabilitation platform and capitalize on its reimbursement infrastructure.
- Pipeline Progress
- The pace at which Lifeward advances its product development pipeline, particularly its POD™ platform.
- Partnership Impact
- Whether the strategic partnership with Oramed Pharmaceuticals will drive significant commercial benefits.
Related topics